In addition, low/negative RRM1 mRNA and protein levels have been reported to correlate significantly with higher response rate and a better prognosis in lung cancer patients treated with gemcitabine-based chemotherapy, and in pancreatic and biliary cancer patients treated with gemcitabine alone [6,9]. Here, RRM1 is linked to lung carcinoma.